Sports Equipment

MediBeacon® Transdermal GFR System receives device approval in China; Peer-reviewed articles on MediBeacon technology published

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.

02-26

BUYING SQUARE Opens Experiential Brand Showroom 'VIBE TWLV' in Brooklyn

NEW YORK,Feb. 25,2025-- BUYING SQUARE,operator of the next-generation digital wholesale platform Catalog Shop,unveiled its experiential brand showroom,VIBE TWLV,in Brooklyn,New York. The 4,270-square-

02-26

Risen Achieves 30.99% Efficiency with HJT-Perovskite Tandem Solar Cells!

NINGBO,China,Feb. 26,2025-- Breaking new ground in solar innovation! Risen\'sHJT (Heterojunction Technology),when combined with aperovskitecell in a tandem structure,has achieved an impressive30.99% e

02-26

Little Artists Students from Singapore Shine at Art Capital 2025 at Grand Palais, Paris

PARIS,Feb. 25,2025-- Little Artists Art Studio,is proud to share the historic debut of their young and rising talents at the prestigious Art Capital Paris: Le Salon des Artistes Français at the

02-26

Guo Guangchang: Fosun Emphasizes Strategic Advancement and Exits, Focuses on Core Businesses, and Leverages Operational Capabilities to Participate in Global Markets

HONG KONG,Feb. 25,2025-- On 21 February,Guo Guangchang,Chairman of Fosun International spoke at the 25th Annual Conference of Yabuli China Entrepreneurs Forum 2025,stating that private enterprises are

02-26

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

SHANGHAI,Feb. 23,2025-- BioCityBiopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist,SC0062,met the 12-week primary endpoint of a reduction in proteinuria in the

02-26

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

Sugemalimab is the world\'s first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugem

02-26

Pudu Robotics Enhances Cleaning Efficiency at Ryugujo Spa Hotel Mikazuki Ryugutei with the Introduction of PUDU SH1

SHENZHEN,China,Feb. 25,2025--Pudu Robotics,a global leader in service robotics,is revolutionizing cleanliness standards at Ryugujo Spa Hotel Mikazuki Ryugutei in Japan,a renowned Japanese hot spring

02-26

MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment

Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial,recommending continued progression as planned

02-26

Emirates to hold its first ever pilot recruitment roadshow in Macao

DUBAI,UAE,Feb. 25,2025-- Emirates,as the international airline based in Dubai,has announced its first series of pilot recruitment roadshows in Macao Special Administrative Region,China to meet the str

02-26

Home Previous 23 24 25 26 27 28 29 Next Tail

10 Items Per Page (Page 26 / 98) Total 972 Items

Newest

1The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

6MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

©copyright 2009-2020 Singapore Info Map